Date  |
|
| Dec 20, 2018 |
CEL-SCI Reports Fiscal 2018 Financial Results and Clinical & Corporate Developments |
| Oct 23, 2018 |
CEL-SCI Receives about $8 Million from Warrant Exercises |
| Sep 28, 2018 |
CEL-SCI Announces Warrants to Expire on October 11, 2018 |
| Sep 14, 2018 |
CEL-SCI Receives $5.4 Million from Warrant Exercises |
| Sep 5, 2018 |
NIH Selects CEL-SCI’s LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program |
| Aug 21, 2018 |
CEL-SCI Corporation Releases Letter to Shareholders |
| Aug 17, 2018 |
CEL-SCI Announces That the NYSE American Approves Plan |
| Aug 15, 2018 |
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study |
| Aug 14, 2018 |
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2018 Financial Results |
| Jul 13, 2018 |
CEL-SCI Reports on NYSE American Noncompliance Notice and Compliance Plan |